LLT1-CD161 Interaction in Cancer: Promises and Challenges

Area of Science:

• Immunology
• Cancer Biology
• Molecular Medicine

Background:

• Immune checkpoint therapy has revolutionized cancer treatment, emphasizing the immune system's role.
• Understanding immune regulation and tolerance has identified new therapeutic targets.
• Lectin-like transcript 1 (LLT1) and its receptor CD161 (NKR-P1A) are key players in immune modulation.

Purpose of the Study:

• To review the current understanding of LLT1/CD161 interactions in cancer.
• To explore the expression, regulation, and functional roles of LLT1 and CD161.
• To assess the therapeutic potential of targeting the LLT1/CD161 pathway.

Main Methods:

• Analysis of recent studies and meta-analyses of single-cell data.
• Review of literature on LLT1 and CD161 expression, regulation, and function.
• Integration of findings within the context of the tumor microenvironment.

Main Results:

• LLT1/CD161 interaction modulates immune responses, though signaling details are still being elucidated.
• Challenges in studying LLT1/CD161 include lack of animal models and reagent specificity.
• Recent data provide new insights into LLT1/CD161 roles in human cancers.

Conclusions:

• LLT1/CD161 interaction is a significant factor in cancer development.
• Targeting LLT1/CD161 represents a promising strategy for future cancer therapies.
• Further research is needed to fully resolve the signaling mechanisms and therapeutic applications.